Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding – Psychedelic Alpha

In this Issue

  • Psychedelics Insiders Draw Up Trump 2.0 Wishlist
  • Rick Doblin Reflects on Lykos’ Strategy as MAPS Settles with FDA
  • Polish Medical Research Agency Set to Provide PLN 16M ($4M) to Psilocybin Study
  • VA Issues Note on Psychedelics for PTSD; Officially Funds Psychedelics Study
  • Alleged Killer of UnitedHealth CEO Apparently Interested in Psychedelics
  • Other Stories including: MDMA Plus Massed Exposure Therapy Protocol Published; Pollan Pushes Back on RFK Jr. Hype; Greenbrook TMS Stock Slumps Following Q3 Earnings; 30 Magic Mushroom Hops Shutter in Ontario; Expression of Concern Issued Over MAPS/Lykos Journal Article; Relmada Therapeutics’ Phase 3 MDD Drug Fails; and more…

***

Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.


Already a member? Log In


   Regular Bulletins covering key topics and trends in the psychedelics space
   Regular articles and deep dives across psychedelic research, policy and business
   Interviews with insiders
   Monthly interactive database and commentary on psychedelic patents
   Quick-take analysis of major developments
   A Library of primers and explainers
   Access to our full back catalogue


Learn more about Pα+